Condition
Supraventricular Tachycardia (SVT)
Total Trials
5
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 4 (2)
Trial Status
Completed3
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07456423Phase 4CompletedPrimary
Adenosine vs. Diltiazem
NCT06993038Phase 4RecruitingPrimary
Adenosine vs Diltiazem for Treatment of SVT in the ED
NCT07086560RecruitingPrimary
PERceptions of Diltiazem Versus ADEnosine for Treatment of Supraventricular Tachycardia in the Emergency Department
NCT06622772Not ApplicableCompletedPrimary
A Novel Valsalva Assist Device for Terminating Supraventricular Tachycardia
NCT02095405Not ApplicableCompletedPrimary
A Study of Caffeine on Cardiac Arrhythmias
Showing all 5 trials